Lifecore Biomedical has cleared a U.S. antitrust waiting-period requirement for its planned sale to Lifecore Inc. The early clearance removes one closing condition, but the transaction is not yet complete: Lifecore stockholders still must approve it, and other closing conditions remain.
The merger agreement, announced September 27, calls for Hazel Merger Sub to merge into Lifecore Biomedical, with Lifecore Biomedical continuing as a wholly owned subsidiary of Lifecore Inc.
- Antitrust review cleared: The Justice Department and Federal Trade Commission granted early termination of the waiting period under U.S. antitrust law, effective November 4.
- Stockholder approval remains: Lifecore Biomedical’s stockholders must adopt the merger agreement at a special meeting. The company has filed a preliminary proxy statement and plans to file a definitive one.
- Other closing conditions remain: Antitrust clearance alone does not complete the transaction. The merger is still subject to the remaining conditions in the agreement.
- Contingent value rights: The company’s risk disclosures refer to contingent value rights to be distributed to stockholders after closing. Their value is uncertain, and holders may receive less than expected or nothing. This update does not provide further details about the rights or the transaction’s financial terms.
What changes for investors: The antitrust waiting period is no longer a barrier to closing, but the deal remains subject to stockholder approval and other conditions. If completed, Lifecore Biomedical would become a wholly owned subsidiary of Lifecore Inc.